Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

NCT01025505 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Treatment
Stem Cell Transplantation

Interventions

DRUG: Nilotinib
DRUG: Imatinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto